Glutamate is believed to be the predominant excitatory neurotransmitter in the networks responsible for itch-related behavior. Beta-lactam antibiotics were shown to exert neuroprotective effects by increasing expression of the glutamate transporter GLT-1. We observed whether repeated administration of the beta-lactam antibiotic ceftriaxone suppresses serotonin-induced itch-related behavior (similarly to the effect of this agent on pain transmission) in mice. Chronic, but not acute, ceftriaxone introductions reduced the number of serotonin-induced scratches; dihydrokainic acid, a selective GLT-1 transporter inhibitor, partly but significantly abolished this effect of ceftriaxone. Our findings suggest that GLT-1 activation by beta-lactam antibiotics looks promising for the treatment of chronic itch.
INTRODUCTION
Glutamate is known to be a principal excitatory amino acid neurotransmitter in the CNS. A few glutamate transporters found in neuronal and glial membranes are primarily responsible for the regulation of extracellular glutamate homeostasis. Among these transporters, glutamate transporter-1 (GLT-1) removes at least 90% of extracellular glutamate and appears to play the pivotal role in terminating synaptic effects of this acid transmitter [1, 2] . Accordingly, drugs stimulating the GLT-1 expression are shown to offer neuroprotection [3] . Among these agents, ceftriaxone, a popular betalactam antibiotic, is being widely studied. It is suggested to contribute to possible effects in many clinical CNS disorders, including Parkinson's disease, stroke, epilepsy, visceral and neuropathic pain, and tolerance and dependence to drugs affecting the CNS [3] [4] [5] [6] [7] [8] [9] . In addition, it is under clinical trials for the treatment of amyotrophic lateral sclerosis.
Itch is an unpleasant (but protective) sensation that provokes the desire to scratch. Although pain and itch are distinct sensations, most noxious chemicals appear to be nonspecific with respect to these phenomena; moreover, spinal cord neuronal mechanisms are suggested to play a significant role not only in pain, but also in itch [10, 11] . Recent researches showed that, similarly to pain sensation, glutamate acts as the major excitatory transmitter for synaptic transmission in the networks involved in the itch-related behavior [12] . As a result, the directions of antipruritic therapies are now expanding from the periphery (skin) to the CNS [13, 14] .
Taking into consideration the similarities between itch and pain sensations, we investigated the effect of activation of the GLT-1 transporter by ceftriaxone on serotonin-induced scratching behavior in mice.
METHODS
Eight-to 12-week-old male Balb/c mice (Center of the Laboratory Animals, Trakya University) were used in the experiments. Animals were maintained under a controlled light cycle (12-12 h light-dark) and temperature (21 ± 2°C) with water and food available ad libitum.
To provoke scratching behavior, 50 µg/50 µl of serotonin was injected intradermally into the rostral part of the back of the experimental mice. Immediately after serotonin administration, the animals were put back into the same cages, and their behavior was videotaped for 30 min; the experimenters remained outside the laboratory Effect of Activation of the GLT-1 Transporter on Serotonin-Induced Scratching during this period. The number of scratching of the injected site by the hindpaws within the observation period was counted as an index of the scratching intensity.
Naive mice were i.p. injected with either saline or ceftriaxone (50, 100, or 200 mg/kg) once daily for 7 days. On day 7, scratching behavior was induced by serotonin administration 30 min after ceftriaxone injection. In a separate animal group, a single injection of ceftriaxone (200 mg/kg, i.p.) was administered in order to evaluate its acute effect. To determine if GLT-1 activation mediates the ceftriaxone effect, the GLT-1 blocker, dihydrokainic acid (DHKA, 10 mg/kg, i.p.), was co-administered with ceftriaxone for 7 days. Drug doses and treatment times were chosen according to previous reports [5, 6, 15] .
A commercial preparation of ceftriaxone (Rocephin, Roche, France) was used; DHKA was purchased from Tocris (Great Britain). Ceftriaxone and DHKA were dissolved in saline and administered i.p. in a volume of 0.1 ml/10 g body mass.
Analysis of variance (ANOVA) was used to carry out statistical comparisons among groups and followed by the Bonferroni t-test. Differences with P values smaller than 0.05 were considered to be statistically significant. All data are expressed below as means ± s.e.m.
RESULTS
In the control group of serotonin-injected mice, the mean number of scratches within the 30-minlong observation period was 46.6 ± 7.6 ( Fig. 1,  1 ). In the groups treated with 50 and 100 mg/kg ceftriaxone, the number of scratches was by about 60% smaller than in the control (P < 0.05; Fig. 1,  2 and 3 ). In the group treated with the greatest dose of ceftriaxone (200 mg/kg), the intensity of suppression of scratching was higher, more than fourfold (P < 0.01; Fig. 1, 4) . Single injections of 200 mg/kg ceftriaxone provided some trend toward decrease in the number of scratches, but the difference from the control was insignificant (Fig. 1, 5 ). Isolated injections of DHKA decreased somewhat the number of scratches. The decrement was about 40%, but the difference did not reach the significance level (mostly because of considerable interindividual dispersion of the values; Fig. 1, 6 ). Introductions of DHKA combined with chronic injections of high doses of ceftriaxone (200 mg/kg) partly but rather significantly suppressed the protective effect of the above antibiotic. In the respective group, the number of scratches within the observation interval was about 78% of the control, i.e., the intensity of scratching was 2.5 times higher than in the group chronically treated with 200 mg/kg ceftriaxone but with no action of the above GLT-1 transporter inhibitor.
Therefore, ceftriaxone introductions reduced serotonin-induced scratching behavior with all the doses used, but only under condition of repeated (chronic) injections. Certain dose dependence was observed in this case; the highest doses (200 mg/kg) provided the greatest anti-itch effect; at the same time, the dependence at smaller doses was not obvious. The GLT-1 transporter inhibitor DHKA (10 mg/kg) elicited some anti-itch action in the case of isolated introduction; at the same time, it significantly abolished the inhibitory effect of ceftriaxone. No significant protective effect was observed in the case of acute ceftriaxone treatment.
DISCUSSION
Pain and itch are distinct but, at the same time, partly similar sensations, both switching on the alert systems to protect the organism of vertebrates from some noxious stimuli. In the periphery, noxious (7); * and **, differences from the control are significant with P < 0,05 and P < 0,01, respectively; +, P < < 0,05 in comparison with group 4.
chemicals are not very specific with respect to pain or itch, and TRP channels are shown to be involved in mediating of both these phenomena [10, 16] . Distinct subsets of itch-specific C-fibers transmit signals from the skin to the superficial spinal dorsal horn regions [17, 18] and, subsequently, to the thalamus and some other suprasegmental structures [11, 18] . Spinal dorsal horn neuronal networks attract great attention of researchers, since these networks are suggested to play important roles in the formation of both pain and itch sensations [10, 11, 13] . Spinal opioids, gastrin-releasing peptide (GRP), glutamate, bradykinin, substance P, serotonin, and histamine receptors were shown (or expected) to be involved in itch, and targeting these spinal receptors by pharmacological agents seems promising for the development of new antipruritic drugs [14] . In addition, first inhibitory interneurons in itch-related networks have been identified in the dorsal spinal cord; loss or suppression of inhibition has been shown to cause pathological itch, similarly to abnormal pain [19] . Deletion of vesicular GLT-2 in the dorsal root ganglia augmented behavioral itch responses [20, 21] . Accordingly, similarly to the pain sensation, glutamate is proposed to be the major neurotransmitter for both GRP-sensitive and insensitive itch-related synaptic transmission in the spinal cord [12] .
Chronic introductions of ceftriaxone were shown to exert anti-nociceptive effects in neuropathic rats; the respective events were considered resulting from specific up-regulation of GLT-1 expression in the spinal cord [8] . When the importance of the amount of released glutamate in the spinal dorsal horn for the itch phenomena is taken into consideration, it can be speculated that isolated action of DHKA should induce scratching behavior. However, we did not observe such effect after isolated administration of this agent. This may be related to an insufficient dose of DHKA. It should also be mentioned that the same dose of the above drug was used in pain studies without any effect on nociception [4] [5] [6] .
Thus, we found that serotonin-induced scratching behavior is suppressed due to repeated treatment with ceftriaxone. In addition to increased expression and function of the GLT-1 in the brain, chronic ceftriaxone administration may also provide GLT-1 up-regulation in the spinal dorsal horn. Although the mechanism of antipruritic activity of the tested beta-lactam antibiotic awaits further exploration, our results indicate that GLT-1 activation by this agent may be a promising option in pharmacotherapy of some chronic itch states.
The study was carried out in accordance with the statements of the Council Directive regarding the protection of animals used for experimental and other scientific purposes (86/609/EEC, 1986, Strasbourg). It was approved by the Animal Care Ethics Committee at the Trakya University and conducted according to the guidelines of the Ethical Committee of the International Association for the study of pain.
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